Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9021743 | 1.00 | HTR4 (0.81) | HTR4KCNH2 | |
| SCHEMBL6843942 | 1.00 | HTR4 (0.81) | HTR4KCNH2 | |
| SCHEMBL9790079 | 0.96 | HTR4 (0.76) | HTR4KCNH2 | |
| SCHEMBL9790086 | 0.96 | HTR4 (0.76) | HTR4KCNH2 | |
| SCHEMBL9790073 | 0.96 | HTR4 (0.76) | HTR4KCNH2 | |
| SCHEMBL3317343 | 0.90 | HTR4 (1.00) | HTR4KCNH2 | |
| SCHEMBL3317348 | 0.90 | HTR4 (1.00) | HTR4KCNH2 | |
| SCHEMBL3317350 | 0.90 | HTR4 (1.00) | HTR4KCNH2 | |
| SCHEMBL6839835 | 0.89 | HTR4 (0.70) | HTR4KCNH2 | |
| SCHEMBL28920790 | 0.89 | HTR4 (0.70) | HTR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040176414-A1 | (+)-Norcisapride | HEYKANTS JOZEF JAN PIETER (BE) | 2004-09-09 | — | — | US | disclosed |
| EP-1000029-B1 | (+)-NORCISAPRIDE USEFUL FOR 5-HT3 AND 5-HT4 MEDIATED DISORDERS | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | disclosed |
| US-20030060485-A1 | (+)-norcisapride | HEYKANTS JOZEF JAN PIETER (BE) | 2003-03-27 | — | — | US | disclosed |
| EP-0640601-B1 | BENZAMIDE DERIVATIVE | HOKURIKU PHARMACEUTICAL (JP) | 1996-12-04 | — | — | EP | disclosed |
| US-5500422-A | FOR TREATING GASTROINTESTINAL DISEASES | HOKURIKU SEIYAKU CO. LTD. (JP) | 1996-03-19 | — | — | US | disclosed |
| US-5395832-A | Gastrointestinal disorders | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-07 | — | — | US | disclosed |
| EP-0640601-A1 | BENZAMIDE DERIVATIVE | HOKURIKU SEIYAKU CO., LTD. (JP) | 1995-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176414-A1 | (+)-Norcisapride | SI, GIPR, SLC10A2 | HTR4 93/4885KCNH2 2695/4885 |
| US-20030060485-A1 | (+)-norcisapride | SI, GIPR, SLC10A2 | HTR4 93/4885KCNH2 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.